REGULATORY

Drugs Being Delivered to Quake-Hit Areas Day after Request: Minister

January 10, 2024

Japan has been able to secure the next-day delivery of pharmaceuticals in central Japan areas struck by a powerful New Year’s Day earthquake, albeit depending on road conditions, Health Minister Keizo Takemi said on January 9.

The quake mainly battered Ishikawa Prefecture’s Noto Peninsula on the Sea of Japan coast. Speaking in a regular press conference, Mr Takemi explained that there are two routes to take requests for drug supplies to the region: 1) the Ishikawa prefectural government receives requests from medical institutions and then contacts local wholesalers, and 2) medical institutions directly send requests to wholesalers.

Requests not only include acute-care medicines needed immediately after the disaster, such as antimicrobials to treat trauma, but also insulin therapies for diabetes, among other treatments, the minister said.

“We have basically been able to distribute these medicines to local medical institutions the day after (the request), although it depends on road conditions,” he said.

On January 7, a mobile pharmacy vehicle reached the northern part of the peninsula called Oku-Noto, and it is now primarily operating in the city of Suzu. He said one more such vehicle will be added on January 9, which will mainly operate in the city of Wajima. “We’ll be dispatching more vehicles once local situations are confirmed,” he said.

REGULATORY

By Ken Yoshino

Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…

By Philip Carrigan

For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…